US$ 24.65
foxo4-dri senolytic peptide human trial 2024 Frontiers FOXO4-DRI: The Senolytic Peptide That
Description
The detection of mouse CII-specific antibodies was carried out by Eu3+-labeled anti-mouse IgG antibody and the DELFIA system (PerkinElmer) according to the manufacturers recommendations

Additional value of serum I-FABP levels for evaluating celiac disease activity in children
Malabsorption Disorders: Conditions such as pernicious anemia, Crohns disease, celiac disease, or a history of gastric bypass surgery can hinder B12 absorption

[6] In all cases, a healthcare provider should evaluate patient history for any contraindication before initiating therapy
